UK's BBI joins Inverness growing family
This article was originally published in Clinica
Inverness Medical Innovations has completed the acquisition of Cardiff, Wales-based diagnostics company BBI. Inverness paid at total of £63.2m ($123.2m) in cash and around 251,300 shares of its common stock for the UK developer of noninvasive lateral flow tests and gold reagents. In December 2007, BBI became one in a string of acquisitions made by Inverness throughout the year (see Clinica No 1286, p 3).
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.